Literature DB >> 2606636

Abnormalities of the liver evaluated by 31P MRS.

D J Meyerhoff1, G S Karczmar, M W Weiner.   

Abstract

Clinical phosphorus-31 magnetic resonance spectroscopy (31P MRS) of the liver requires the use of whole-body magnets and of spectroscopy techniques that acquire signal from defined volumes-of-interest within the liver. Such localization techniques and recent clinical studies are briefly reviewed. These studies indicate that (1) high phosphomonoester levels are present in liver diseases involving structural damage, and (2) that MRS of liver tumors may provide a sensitive and rapid indication of response to cancer therapy. Abnormalities of the liver such as alcoholic liver disease, viral hepatitis, and metastasis were analyzed to determine hepatic acid/base status (pH) and to derive absolute molar concentrations of hepatic phosphorus metabolites rather than metabolite ratios. These parameters allow diagnosis and differentiation of several liver pathologies, suggesting an increasing future role of MRS in medical investigation, clinical diagnosis, and patient treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2606636     DOI: 10.1097/00004424-198912000-00012

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  2 in total

1.  Application of localized ³¹P MRS saturation transfer at 7 T for measurement of ATP metabolism in the liver: reproducibility and initial clinical application in patients with non-alcoholic fatty liver disease.

Authors:  Ladislav Valkovič; Martin Gajdošík; Stefan Traussnigg; Peter Wolf; Marek Chmelík; Christian Kienbacher; Wolfgang Bogner; Michael Krebs; Michael Trauner; Siegfried Trattnig; Martin Krššák
Journal:  Eur Radiol       Date:  2014-03-20       Impact factor: 5.315

2.  Altered phosphorylation status, phospholipid metabolism and gluconeogenesis in the host liver of rats with prostate cancer: a 31P magnetic resonance spectroscopy study.

Authors:  P C Dagnelie; J D Bell; S C Williams; T E Bates; P D Abel; C S Foster
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.